Compare Gilead Sciences, Inc. (GILD) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nerdwallet Inc — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Nerdwallet Inc trades at $9.59 (market cap $627.06M). The key difference: Gilead Sciences, Inc. is far larger — about 260.8× Nerdwallet Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| GILD | NRDS | |
|---|---|---|
Market Cap | $163.51B | $627.06M |
Sector | Health | Financials |
52-Week High | $155.80 | $15.93 |
52-Week Low | $108.22 | $7.58 |
Enterprise Value | $178.05B | $541.36M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
NerdWallet (NRDS) trades at $9.47, showing modest daily gains. The stock presents a mixed technical picture with a bearish overall signal but strong fundamental metrics, including a low P/E of 10.25, a high gross margin of 93.04%, and consistent earnings beats. Recent quarterly results have exceeded expectations, and analyst consensus is bullish with a $12.75 price target, implying significant upside.
The outlook is positive due to attractive valuation, strong profitability, and a successful business pivot. Key risks include a bearish technical trend, potential revenue headwinds from declining search traffic, and execution challenges in sustaining high growth. The stock offers a compelling risk-reward profile for value-oriented investors seeking exposure to financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
